2026-01-02 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS) based on the data provided, broken down into sections as requested:

**1) Return Rate Comparison**

*   **Ticker:** HIMS
*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that provides personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 109.66%
*   **S&P 500 (VOO) Cumulative Return:** 70.04%
*   **Divergence:**
    *   Current: 34.4
    *   Relative Divergence: 29.6

    **Analysis:** HIMS has significantly outperformed the S&P 500 with a much higher cumulative return.  The divergence of 34.4 indicates that HIMS has generated a greater return compared to the S&P 500 over the period of analysis. The relative divergence of 29.6 suggests that the current divergence is relatively low compared to its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD     | Alpha    | Beta   | Cap(B) |
|------------|----------|---------|----------|--------|--------|
| 2020-2022  | -19.0%   | 99.9%   | -17.0%   | 0.7    | 1.5    |
| 2021-2023  | -65.0%   | 99.9%   | -66.0%   | 1.6    | 2.0    |
| 2022-2024  | 119.0%  | 98.7%   | 99.0%    | 1.7    | 5.5    |
| 2023-2025  | 114.0%  | 98.7%   | 52.0%    | 2.1    | 7.4    |

**Analysis:** The table shows varying performance over different periods. CAGR shows strong gains in the most recent periods (2022-2024 and 2023-2025) after earlier losses.  The Maximum Drawdown (MDD) is very high across all periods, indicating significant price volatility and risk. Alpha values show that HIMS generally underperformed relative to its beta in earlier periods, but dramatically outperformed in the 2022-2024 timeframe. The Beta consistently exceeds 1, indicating the stock is more volatile than the market. The Market Cap has increased significantly.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 32.47
*   **Last-Market Data:** price: 32.47, previousClose: 33.04, change: -1.73
*   **5-day SMA:** 33.718
*   **20-day SMA:** 36.247
*   **60-day SMA:** 41.9972

**Analysis:** The stock is currently trading below all three moving averages (5-day, 20-day, and 60-day). This suggests a short-term downward trend. The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA, reinforcing this downward trend. The price decreased from the previous close, confirming a short-term decline.

**3) Indicator Analysis**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommended)
*   **RSI:** 17.05 (Oversold)
*   **PPO:** -0.46 (Negative)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (26 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -3.2 (Short-term decline)
*   **Expected Return (%):** 329.75%

**Analysis:**

*   The MRI suggests a medium investment level.
*   The RSI of 17.05 indicates that the stock is oversold, which could signal a potential for a price rebound.
*   The negative PPO suggests a bearish trend.
*   The hybrid signal suggests a strong buy recommendation according to the MRI.
*   The negative change in relative divergence over the last 20 days confirms a short-term downward trend.
*   The expected return of 329.75% is very high, suggesting significant potential upside if invested for the long term (2+ years), but also implies high risk.

**4) Recent News & Significant Events**

*   **[2025-12-16] Hims & Hers Health (HIMS): Taking Stock of Valuation After a Sharp 90‑Day Pullback:**  Suggests the stock has experienced a significant decline and investors are re-evaluating its worth.
*   **[2025-11-17] Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization:**  This is generally seen as a positive sign, indicating the company believes its stock is undervalued and is willing to invest in itself.
*   **[2025-12-29] Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar:**  Highlights investor uncertainty due to expansion plans and broader economic factors.
*   **[2026-01-01] HIMS Stock Falls -8.7% With A 7-day Losing Spree On Valuation Concerns:** Reinforces concerns about the stock's valuation and recent negative performance.
*   **[2025-12-13] $HIMS stock fell 6% this week. Here's what we see in our data.:** Indicates recent underperformance.
*   **[2025-12-29] Why HIMS Stock Is Up 36% In 2025:** Contrasts the recent negative news, highlighting the overall positive performance for the year.

**Analysis:** The news sentiment is mixed. While there's positive news about a share repurchase program and overall yearly gain, the recent headlines focus on valuation concerns, a sharp pullback, and recent price declines. This suggests a period of uncertainty and increased volatility.

**4-2) Analyst Opinions**

*   **Analyst Consensus:** None reported.
*   **Mean (1=StrongBuy~5=Sell):** -
*   **Opinions:** 12
*   **Target Price (avg/high/low):** 44.67 / 85.00 / 25.00

**Analysis:** 12 analysts have given opinions. The average target price of $44.67 is significantly higher than the current price of $32.47, suggesting analysts generally believe the stock is undervalued and has upside potential. However, there is a wide range in target prices (from $25 to $85), indicating uncertainty and disagreement among analysts.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-11-03 | 0.07 | 0.60 B$  |
| 2025-08-04 | 0.19 | 0.54 B$  |
| 2025-05-05 | 0.22 | 0.59 B$  |
| 2024-11-04 | 0.35 | 0.40 B$  |
| 2025-11-03 | 0.35 | 0.40 B$  |

**Analysis:** Revenue is growing over the period, from $0.40B in 2024-11-04 to $0.60B in 2025-11-03, with some fluctuations in between. The EPS shows a decline from the value in 2024.
    *   The doubled reporting of 2025-11-03 and 2024-11-04 needs clarification.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $0.60B   | 73.80%        |
| 2025-06-30   | $0.54B   | 76.39%        |
| 2025-03-31   | $0.59B   | 73.50%        |
| 2024-12-31   | $0.48B   | 76.81%        |
| 2024-09-30   | $0.40B   | 79.16%        |

**Analysis:** Revenue has generally increased over the last five quarters. The profit margin has fluctuated, but remains high, indicating good cost control and pricing power.

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
|--------------|----------|----------|
| 2025-09-30   | $0.58B   | 2.72%    |
| 2025-06-30   | $0.56B   | 7.55%    |
| 2025-03-31   | $0.55B   | 9.01%    |
| 2024-12-31   | $0.48B   | 5.46%    |
| 2024-09-30   | $0.44B   | 17.18%   |

**Analysis:** Equity has steadily increased. The Return on Equity (ROE) has fluctuated, but has generally decreased over the last year, indicating a lower return generated on shareholder equity.

**7) Comprehensive Analysis**

Hims & Hers Health Inc. (HIMS) has demonstrated strong revenue growth and high profit margins. It has outperformed the S&P 500 over the long term, though with high volatility. Recent news indicates a sharp pullback due to valuation concerns, yet the stock is still up significantly in 2025. Analyst target prices suggest potential upside, but with significant disagreement. The recent stock price action is negative, trading below key moving averages, and the RSI indicates oversold conditions, which can lead to a strong buy signal.

The high expected return of 329.75% suggests significant potential for long-term investors, but also considerable risk. The high Beta values indicate a high volatility stock. The share repurchase program is a positive sign, but the company's future plans, such as the Ohio buildout, and broader macroeconomic factors could impact the stock.

**In summary, HIMS appears to be a high-growth, high-risk, and potentially high-reward stock. The recent pullback may present a buying opportunity, but investors should be aware of the risks and conduct further due diligence before investing.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.